Literature DB >> 7789392

Indium-111 octreotide scintigraphy in neurofibromatosis.

C L Maini1, R P Cioffi, A Tofani, R Sciuto, M Fontana, C M Carapella, M Crecco.   

Abstract

Scintigraphy with the radiolabelled somatostatin analogue indium-111-DTPA-D-Phe-1-octreotide has recently been proposed for the imaging of CNS neoplasms expressing somatostatin receptors. While meningiomas are imaged with high sensitivity, neurinomas do not take up octreotide owing to the lack of somatostatin receptors. Neurofibromatosis is a relatively uncommon disorder in which meningiomas and neurinomas often occur in the same patient. Differential diagnosis between these two tumours by computed tomography and magnetic resonance imaging can be difficult. This study reports on 111In-octreotide scintigraphy in four patients with neurofibromatosis. 111In-octreotide scintigraphy was shown to be very helpful in the in vivo differential diagnosis: all four meningiomas showed intense tracer uptake, while all 15 neurinomas were negative (P < 0.001 by Fisher's exact test). It may be concluded that scintigraphy with 111In-octreotide is a useful diagnostic procedure in neurofibromatosis, complementing standard neuroradiological imaging procedures.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7789392     DOI: 10.1007/bf01081513

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  9 in total

Review 1.  The role of somatostatin and its analogs in the diagnosis and treatment of tumors.

Authors:  S W Lamberts; E P Krenning; J C Reubi
Journal:  Endocr Rev       Date:  1991-11       Impact factor: 19.871

2.  Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference.

Authors: 
Journal:  Arch Neurol       Date:  1988-05

3.  High incidence of somatostatin receptors in human meningiomas: biochemical characterization.

Authors:  J C Reubi; R Maurer; J G Klijn; S Z Stefanko; J A Foekens; G Blaauw; M A Blankenstein; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  1986-08       Impact factor: 5.958

4.  MR imaging of meningiomas including studies with and without gadolinium-DTPA.

Authors:  G M Bydder; D P Kingsley; J Brown; H P Niendorf; I R Young
Journal:  J Comput Assist Tomogr       Date:  1985 Jul-Aug       Impact factor: 1.826

Review 5.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

6.  Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences.

Authors:  K Scheidhauer; G Hildebrandt; C Luyken; K Schomäcker; N Klug; H Schicha
Journal:  Horm Metab Res Suppl       Date:  1993

7.  [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.

Authors:  W H Bakker; R Albert; C Bruns; W A Breeman; L J Hofland; P Marbach; J Pless; D Pralet; B Stolz; J W Koper
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

8.  Somatostatin receptors in meningiomas: a scintigraphic study using 111In-DTPA-D-Phe-1-octreotide.

Authors:  C L Maini; A Tofani; R Sciuto; C Carapella; R Cioffi; M Crecco
Journal:  Nucl Med Commun       Date:  1993-07       Impact factor: 1.690

9.  Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system.

Authors:  J C Reubi; W Lang; R Maurer; J W Koper; S W Lamberts
Journal:  Cancer Res       Date:  1987-11-01       Impact factor: 12.701

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.